{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058996","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.158336+00:00","generated_at":"2026-06-08T19:41:24.814478+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab","bullets":["GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).","Sight-threatening complications risk reduced 89%: 2.3% vs 21.0% (p<0.0001).","DME development risk reduced 95%: 0.7% tarcocimab vs 13.7% sham.","Kodiak pauses then resumes tarcocimab; plans one additional pivotal study for single BLA for wAMD, RVO, NPDR.","Serious ocular adverse events and intraocular inflammation rates similar between groups."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058996","json":"https://secwatch.observer/filing/0000950170-23-058996.json","markdown":"https://secwatch.observer/filing/0000950170-23-058996.md","text":"https://secwatch.observer/filing/0000950170-23-058996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/0000950170-23-058996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/kod-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:41:24.814478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}